Compound Evidence File
#EC-2026-0199
AICAR Oral
Filed under Oral Tablets. The bureau holds 101 laboratory returns for this compound from 38 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
38 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 7 Jan 2026 | 15 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Apr 2026 | 28 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Jan 2026 | 12 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 25 Feb 2026 | 25 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 10 May 2026 | 1 Jun 2026 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 1 | 10.0 | 10.0 | 10.0 | 9 Jun 2025 | 9 Jun 2025 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Jun 2026 | 10 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 20 Jan 2026 | 28 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 26 Dec 2025 | 19 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 19 Nov 2025 | 16 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Dec 2025 | 12 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 1 Dec 2025 | 15 Feb 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 9.9 | 15 Apr 2026 | 10 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Apr 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 8.9 | 8.1 | 9.8 | 21 May 2026 | 21 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.6 | 7.0 | 9.3 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.6 | 7.2 | 10.0 | 23 May 2026 | 23 May 2026 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 8.6 | 8.6 | 8.6 | 17 Dec 2024 | 17 Dec 2024 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.5 | 6.8 | 10.0 | 21 May 2026 | 21 May 2026 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 8.5 | 8.5 | 8.5 | 24 Apr 2025 | 24 Apr 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 7.9 | 7.4 | 8.4 | 23 May 2026 | 23 May 2026 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 7.9 | 7.9 | 7.9 | 21 May 2025 | 21 May 2025 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 7.1 | 7.1 | 7.1 | 3 Jul 2025 | 3 Jul 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 11 | 7.0 | 5.2 | 10.0 | 2 Apr 2025 | 26 Jan 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 6.7 | 6.7 | 6.7 | 28 Mar 2025 | 28 Mar 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 6.6 | 6.6 | 6.6 | 16 Mar 2025 | 16 Mar 2025 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 6.0 | 6.0 | 6.0 | 27 Feb 2025 | 27 Feb 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 5.7 | 5.7 | 5.7 | 13 Jun 2025 | 13 Jun 2025 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 5.3 | 5.3 | 5.3 | 14 Jan 2025 | 14 Jan 2025 |
| Zztai PeptideCASE #VI-2026-0192 | X | 1 | 4.4 | 4.4 | 4.4 | 7 May 2025 | 7 May 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 1 | 3.5 | 3.5 | 3.5 | 8 Jul 2025 | 8 Jul 2025 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 2.4 | 2.4 | 2.4 | 13 Jun 2025 | 13 Jun 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 0.4 | 0.4 | 0.4 | 27 Feb 2025 | 27 Feb 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 0.0 | 0.0 | 0.0 | 7 May 2025 | 7 May 2025 |
Open any subject to view the batch-level evidence for AICAR Oral alone.